LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Adam Brufsky, and Dr. William Gradishar discuss the practice-changing impact of ASCO presentations in breast cancer.
On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top breast cancer clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June4-8, 2021. Dr. Kevin Knopf from UCSF moderated the discussion between breast cancer KOLs Dr. Adam Brufsky from the University of Pittsburgh Medical Center and Dr. William Gradishar from Northwestern University.
The discussion covered ASCO abstract #1063 Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results, ASCO abstract #1068 Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3Cam), and ASCO abstract #1055 Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.
Watch this video for the full discussion:
Our ASCO Panel Series covered six therapeutic areas including breast cancer. Click below to read more about them and watch their video analysis.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.